Cost-Utility Analysis of Drug Treatments in Patients with Polypoidal Choroidal Vasculopathy in Thailand.

Sermsiri SangroongruangsriUsa ChaikledkaewPrut HanusahaTanapat RatanapakornPaisan Ruamviboonsuk

Published in: ClinicoEconomics and outcomes research : CEOR (2021)

None of the drug treatments for PCV was cost-effective in the Thai context. The decreased price of verteporfin is required to support the inclusion of IVB+vPDT in the Thai National List of Essential Medicines for the treatment of PCV.

Keyphrases

age related macular degeneration
optical coherence tomography
adverse drug
quality improvement
drug induced